OBJECTIVES

To perform a complete economic evaluation of the use of ixazomib in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received previous therapy in Mexico.

METHODS

: A cost-effective analysis was carried out using a Markov model, taking into account the results obtained with the systematic review of the clinical evidence. The model evaluates the use of Ixazomib in combination with lenalidomide and dexamethasone for the treatment of patients with Multiple Myeloma who have received previous therapy, against the following treatment regimens: Daratumumab/Lenalidomide/Dexamethasone, Carfilzomib/Lenalidomide/Dexamethasone, Pomalidomide/Bortezomib/Dexamethasone, Bortezomib/Lenalidomide/Dexamethasone and Carfilzomib/Lenalidomide/Dexamethasone, using life-years gained (LYG) as the main outcome. Direct medical costs of each scheme treatment were taken into consideration; the time horizon was 10 years with a discount rate of 5% for health costs and consequences from the perspective of Public Health institutions in Mexico.

RESULTS

The analysis showed that Ixazomib/Lenalidomide/Dexamethasone is more effective in the treatment of patients with Multiple Myeloma who have at least received one previous therapy with a total of 5.771 LYG, and an average cost of $ 135,486.15 per patient in ten years, generating an ICER of $9,961.18 compared to Bortezomib/Lenalidomide/Dexamethasone, which is the least expensive scheme. Additionally, the results of the sensitivity analysis showed that the model is robust.

CONCLUSIONS

: Ixazomib/Lenalidomide/Dexamethasone turns out to be the most effective option and the second least expensive option, making it a cost-effective option in the treatment of patients with multiple myeloma that have received prior therapy, being in the threshold between one and two GDP per capita.